Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Halozyme Therapeutics Stock Down 2.0 %
Shares of Halozyme Therapeutics stock traded down $1.19 during trading on Monday, hitting $57.96. 1,414,542 shares of the stock traded hands, compared to its average volume of 1,294,096. The stock has a market cap of $7.14 billion, a P/E ratio of 16.90, a PEG ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The company has a fifty day moving average price of $54.53 and a two-hundred day moving average price of $54.72.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.
Institutional Investors Weigh In On Halozyme Therapeutics
Several hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $10,032,000. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Armis Advisers LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $295,000. GF Fund Management CO. LTD. bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $128,000. Finally, Novem Group bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $841,000. 97.79% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have issued reports on HALO. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.
View Our Latest Stock Report on HALO
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
See Also
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
